| 71.47 |  +0.39 / +0.55% |
Data as of 4:00pm ET | Day’s Change |
| 71.00 |  -0.4731 / -0.66% |
Volume: 884.00 |
| Gilead's Entry Into Cancer Therapy 12:51pm / MotleyFool.com | Setback for Valeant Pharma - Analyst Blog May 29 / Zacks.com |
| Nektar Presents Data on Oncology Candidates - Analyst Blog Jun 05 / Zacks.com | Encouraging Data from Novartis - Analyst Blog May 29 / Zacks.com |
| CHMP Positive on Novartis' Lucentis - Analyst Blog Jun 04 / Zacks.com | Encouraging Data from Novartis - Analyst Blog May 29 / Zacks.com |
| FDA Accepts Teva sNDA - Analyst Blog May 31 / Zacks.com | Valeant Pharma to Buy Bausch+Lomb - Analyst Blog May 28 / Zacks.com |
| Previous close | 71.08 |
| Today’s open | 71.07 |
| Day’s range | 70.57 - 71.47 |
| Volume | 1,060,044 |
| Average volume (3 months) | 1,555,479 |
| Market cap | $172.1B |
| Dividend yield | 3.40% |
| Earnings growth (last year) | +10.15% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +6.00% |
| Revenue growth (last year) | +3.88% |
| P/E ratio | -- |
| Price/Sales | 2.52 |
| Price/Book | 2.28 |
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer Inc | +0.63 | +2.29% |
| MRKMerck & Co Inc | -0.13 | -0.27% |
| SNYSanofi SA | +0.36 | +0.68% |
| GSKGlaxoSmithKline PLC | +0.58 | +1.15% |
| Next reporting date | July 17, 2013 |
| EPS forecast (this quarter) | $1.28 |
| Annual revenue (last year) | $60.8B |
| Annual profit (last year) | $10.2B |
| Net profit margin | 16.77% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Joseph Jimenez, MBA |
Chief Financial Officer Harry Kirsch |
Corporate headquarters Basel, Basel-stadt (basle Town) |
.
